Reducing the Burden and Improving QoL in Non-Cystic Fibrosis Bronchiectasis: Insights on Challenging Cases

Program Overview

Patient Case Module 2 of 2

Non-cystic fibrosis bronchiectasis (NCFBE) is an irreversible, chronic lung disease in which patients experience airway dilation and bronchial wall injury secondary to repeated infections and inflammation, posing highly variable but potentially major health burdens to patients and society. There are no approved therapies specifically indicated for its treatment. In this activity, an interprofessional expert panel tackles difficult cases in NCFBE that have been crowdsourced from practicing clinicians all over the United States. What would you do? Listen as they describe diagnostic and treatment challenges and how healthcare professionals can work as a team to overcome them.

Link to Panel Discussion

Link to Module 1

0.25 CE Credit(s)

Expires: January 9, 2024

Target Audience

Pulmonology, infectious diseases, primary care, and radiology clinicians managing patients with NCFBE.

Educational Objectives

Upon completion of this activity, participants should be better able to:

Utilize clinical practice guidelines for non-cystic fibrosis bronchiectasis (NCFBE) diagnosis
Integrate the unique roles and responsibilities of the interprofessional care team when diagnosing and treating patients with NCFBE
Examine emerging treatments targeting the underlying immune mediated pathophysiologic processes of NCFBE

Activity Faculty

Mark L. Metersky, MD, FCCP (Chair)

Professor, Medicine
Associate Chief of Service, Department of Medicine
Chief, Division of Pulmonary, Critical Care and Sleep Medicine
Director, Center for Bronchiectasis Care
UConn Health
Farmington, CT

Margaret M. Johnson, MD

Professor, Medicine
Mayo Clinic College of Medicine and Science
Consultant, Pulmonary Medicine
Mayo Clinic
Jacksonville, FL

Molly Mailes, MSN, RN, MEDSURG-BC

Nurse Program Coordinator, Adult Cystic Fibrosis
Mayo Clinic
Jacksonville, FL

Resources

Provider Statement

Provided by RMEI Medical Education, LLC

Supporter Statement

This activity is supported by an educational grant from Insmed. 

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Margaret M. Johnson, MD, has no relevant financial relationship(s) with ineligible companies to disclose.

Molly Mailes, MSN, RN, MEDSURG-BC, has no relevant financial relationship(s) with ineligible companies to disclose.

Mark L. Metersky, MD, FCCP, has relevant financial relationships with Boehringer Ingelheim, Insmed, Tactile Medical, Zambon (Consultant); AN2, Renovion (Other: Data Safety Monitoring Board); Insmed (Researcher).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers

RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation and Request for Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at [email protected].

Users must:

Read the learning objectives and faculty disclosures
Participate in the activity
Complete the activity evaluation and attest to credit

There is no fee to participate.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Copyright Statement

Featured RMEI CE Activities